Evidence map›Paper›PMID 31964245›Full record

ArticleTechnology in cancer research & treatment

MicroRNA-425-5p Inhibits Lung Cancer Cell Growth

Xi Yu, Hong Zheng, Rongfei Sun, Xuejiao Qian, Ping Jiang, Bo Yang, Jiangbo Liu, Xiaoping Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Xi YuDepartment of Respiratory, Tianjin First Central Hospital, Tianjin, China.
Hong ZhengDepartment of Respiratory, Tianjin First Central Hospital, Tianjin, China.
Rongfei SunDepartment of Respiratory, Tianjin First Central Hospital, Tianjin, China.
Xuejiao QianDepartment of Respiratory, Tianjin First Central Hospital, Tianjin, China.
Ping JiangDepartment of Respiratory, Tianjin First Central Hospital, Tianjin, China.
Bo YangDepartment of Thoracic Surgery, Tianjin First Central Hospital, Tianjin, China.
Jiangbo LiuDepartment of Respiratory, Tianjin First Central Hospital, Tianjin, China.
Xiaoping LiDepartment of Thoracic Surgery, Tianjin First Central Hospital, Tianjin, China.ORCID 0000-0002-4803-4539
Tianjin First Center Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is the most common cancer type with increasingly high incidence. MicroRNAs provide the potential biomarkers for lung cancer treatment. Thus, we aimed to investigate the function of microRNA-425-5p in lung cancer development and the underlying mechanisms. MicroRNA-425-5p overexpression inhibited A549 lung cancer cell proliferation

Indexed as

Cell ProliferationGene Expression Regulation, NeoplasticGenes, Tumor SuppressorSignal TransductionAnimalsApoptosisCell MovementCell Transformation, NeoplasticHumansLung NeoplasmsMiceMice, NudeMicroRNAsTranscription Factor TFIIIBTumor Cells, CulturedXenograft Model Antitumor AssaysBRF2 protein, humanMicroRNAsMIRN425 microRNA, humanTranscription Factor TFIIIBbiomarkercell growthlung cancermicroRNA-425-5pTFIIB-related factor 2

Identifiers

PMID31964245
PMCPMC6978817
OpenAlexW3002008729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.